Product Information for the fully human monoclonal antibody denosumab have been updated regarding the potential risk of QT interval prolongation associated with hypocalcaemia. Hypocalcaemia is a known effect of denosumab and was already captured in the PI, the TGA said in its latest Medicines Safety Update. The potential risk of QT interval prolongation was identified ...
Denosumab PI updated to reflect potential cardiac risk
19 Aug 2016